

---

## Rameda Announces New Chairman and Additions to its Board of Directors

**Cairo, Egypt — 3 June 2026** — Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents ("Rameda" or "the Company"), one of Egypt's leading pharmaceutical manufacturers, announces the appointment of **Mr. Sharif Ahmed El Akhdar** as Chairman of its Board of Directors, alongside the addition of new members to the Company's Board.

Mr. El Akhdar joins the Board as a non-executive Chairman representing LVP Pharma, which holds an approximately 23.15% stake in the Company. LVP Pharma is the investment vehicle of LimeVest, the Egypt/Saudi-focused healthcare platform. Joining the Board alongside him as non-executive board members representing LVP Pharma are **Ms. Dalia El Shal** and **Mr. Ahmed Abou Hendia**. The appointments were approved at a meeting of the Board of Directors held on 1 June 2026, following the completion of LVP Pharma's strategic investment in the Company.

The Board now comprises thirteen members, bringing together representatives of the Company's principal shareholders alongside independent directors, reflecting Rameda's continued commitment to strong corporate governance and balanced board representation.

---

*"I am honored to take on the role of Chairman of Rameda at a pivotal point in its journey. Rameda is exactly the kind of platform we believe in — a resilient, well-run pharmaceutical business with a trusted name and significant room to grow. Together with the Board and management team, I look forward to building on that foundation to accelerate growth, deepen institutionalization, support regional expansion initiatives, and create lasting value for our shareholders and the patients we serve."*

— **Mr. Sharif Ahmed El Akhdar, Chairman of the Board of Directors**

---

The Board and the incoming Chairman extended their sincere appreciation to Mr. Ayman Abbas, the outgoing Chairman, for his valuable contributions and dedicated leadership during his tenure. Mr. Abbas will continue to serve on the Board as a non-executive member, ensuring continuity as the Company enters its next phase of growth.

### **Mr. Sharif Ahmed El Akhdar — Chairman (Non-Executive)**

Mr. El Akhdar is the Founder and Chairman of LimeVest, an Egypt/Saudi-focused healthcare platform he established in 2017, where he chairs the Investment Committee and leads firm strategy, fundraising, and deal origination. He previously served as a Partner at BPE Partners (formerly Beltone Private Equity) from 2008, leading investments in Madinet Nasr Housing and Development, Total Egypt, PGESCo, and Pickalbatros. Earlier in his career he worked at American Capital Strategies, one of the largest US publicly-traded alternative asset managers, and began as a management consultant with Abt Associates. He currently serves on the boards of the Housing and Development Bank (HDBK.CA) — where he chairs the Risk and Investment Committees — Alexandria New Medical Center (AMES.CA), Egyptian Resorts Company, and several other healthcare and investment companies. He holds an MSc in Finance from the George Washington University School of Business and a BA in Accounting and Economics from the American University in Cairo.

### Ms. Dalia El Shal — Non-Executive Board Member

Ms. El Shal is the Vice Chairman and Group CFO of LimeVest Partners Healthcare, overseeing financial strategy, portfolio operations, budgeting, forecasting, treasury, and investment due diligence across the group. She serves on the boards of several healthcare and pharmaceutical companies within the LimeVest portfolio, including Alexandria New Medical Center, Eye International Subspecialty Center, Dar Al Teb for Medical Services, ArtPharma, Ebtesama Hospital, and NSA Diagnostics. A Certified Public Accountant (CPA) with over 20 years of experience, Ms. El Shal has held senior finance leadership positions across the healthcare, FMCG, industrial, and commercial sectors. Her expertise includes financial management, strategic planning, risk management, tax optimization, digital transformation, and operational efficiency. Prior to joining LimeVest, she served as Group CFO of Ray-Lab Holdings and held senior finance leadership roles at Juhayna Group. She began her career with General Motors Egypt and J&P International Construction. Ms. El Shal holds a BA in Commerce & Business Administration from Helwan University, is a CPA (California), and completed the Senior Executive Program at the Indian Institute of Management Ahmedabad.

### Mr. Ahmed Abou Hendia — Non-Executive Board Member

Mr. Abou Hendia is an Attorney at Law before the Court of Cassation and the Founder and Managing Partner of Abou-Hendia Law Firm (2005–present). A graduate of Ain Shams University Faculty of Law, he serves as legal consultant to numerous local and international companies and holds memberships in the Egyptian Bar Association (Supreme Degree), the International Bar Association, and the Cairo Regional Centre for International Commercial Arbitration, among others. He brings extensive board experience across leading Egyptian listed companies, including Elsewedy Electric, the Housing and Development Bank, Egyptian Resorts Company, Arabian Cement, and Cairo Pharmaceuticals and Chemical Industries, and serves on the Boards of Trustees of Nile University and Misr International University.

## Board of Directors

The Company's Board of Directors now comprises the following members:

| Name   | Board Role  | Represents                       |
|--|---|----------------------------------|
| Mr. Sharif Ahmed Mohamed El Sayed El Akhdar    | Chairman (Non-Executive)                            | LVP Pharma                       |
| Mr. Shamel Fahim Lotfy Abou El Fadl            | Vice Chairman (Non-Executive)                       | Equinox Pharma Holding Limited   |
| Mr. Amr Abdullah Morsy Mosaad                  | Managing Director (Executive)                       | Equinox Pharma Holding Limited   |
| Mr. Mahmoud Mostafa Mahmoud Salah El Din Fayek | Managing Director for Financial Affairs (Executive) | Equinox Pharma Holding Limited   |
| Dr. Mohamed Farouk Mohamed Abdel Magid         | Non-Executive Board Member                          | Equinox Pharma Holding Limited   |
| Mr. Ayman Mamdouh Mohamed Fathy                | Non-Executive Board Member                          | Equinox Pharma Holding Limited   |
| Mr. Karim Mamdouh Mohamed Zahran               | Non-Executive Board Member                          | Equinox Pharma Holding Limited   |
| Ms. Dalia El Sayed Mohamed El Mansy El Shal    | Non-Executive Board Member                          | LVP Pharma                       |
| Mr. Ahmed Saad El Din Abdo Abou Hendia         | Non-Executive Board Member                          | LVP Pharma                       |
| Mr. Mohamed Galal Ahmed El Shoura              | Non-Executive Board Member                          | Equity B.V.                      |
| Mr. Daniel Lee Grice                           | Non-Executive Board Member                          | Seventh Saudi Investment Company |
| Mr. Hatem Ahmed El Sayed Soliman               | Independent Director                                | —                                |
| Ms. Mirna Essam El Din Mohamed Aref            | Independent Director                                | —                                |



---

## Investor Relations Contact for Rameda

Khaled Daader – Head of Investor Relations & M&A

[Khaled.daader@rameda.com](mailto:Khaled.daader@rameda.com)

[ir@rameda.com](mailto:ir@rameda.com)

## About Rameda

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.

## Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above. Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.